GET DAILY SIGNALSMiNK Therapeutics (INKT) Falls -12.4% Over 30 Days as Clinical-Stage Biotech Navigates Volatility
Key Takeaways
- MiNK Therapeutics (INKT) shares declined roughly 12.4% over the last 30 days, falling from a closing price of $12.13 on September 28 to $10.63 on October 27.
- The pullback followed a September rally that carried the stock to a recent peak near $12.73 in early October before momentum reversed.
- Over the most recent quarter, the stock is essentially flat, up about 0.9%, reflecting a volatile, range-bound trading pattern.
- MiNK remains a clinical-stage biotech with no approved products; its lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy in a randomized Phase 2 trial for acute lung injury and critical illness.
- Low trading liquidity and a micro-cap valuation make INKT susceptible to sharp, sentiment-driven swings even without a single company-specific announcement.
- Investors can review detailed Price Targets, Earnings, and Forecast data for INKT on dedicated pages.
- For additional market intelligence, explore Trending AI Robots.
MiNK Therapeutics (INKT) Company Overview and Market Position
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies designed to restore immune balance across cancer and immune-mediated diseases. Its lead program, agenT-797, is an unmodified iNKT cell therapy that can be administered without HLA matching or lymphodepleting chemotherapy, positioning it as a potentially scalable and rapidly deployable treatment.
The company, which was spun out of Agenus, is advancing agenT-797 in severe acute lung injury and acute respiratory distress syndrome (ARDS), as well as in solid tumors and graft-versus-host disease (GvHD). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow INKT for its differentiated cell-therapy platform, non-dilutive funding strategy, and a pipeline of catalysts tied to clinical data readouts, though the company remains pre-revenue and heavily dependent on external financing.
MiNK Therapeutics (INKT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INKT declined from a closing price of $12.13 on September 28 to $10.63 on October 27, a drop of approximately 12.4%. The decline was concentrated in the first half of October, when the stock pulled back from its early-October high near $12.73 and briefly traded below $9.40 before stabilizing in the low-to-mid $10 range.
The broader quarterly picture is more balanced. Three months earlier, on July 28, the stock closed at $10.54, meaning the quarter's net change is a modest gain of roughly 0.9%. In between, INKT rallied through August and September before giving back most of those gains, underscoring a choppy, range-bound environment rather than a sustained directional trend.
What Drove INKT Stock Price in the Last 30 Days
The 30-day decline does not appear tied to a single company-specific disclosure. Instead, the move reflects a combination of profit-taking after a September run-up, thin trading liquidity, and broader risk sentiment surrounding small-cap clinical-stage biotechs. From what I see, INKT trades on modest daily volume, and micro-cap names with concentrated clinical catalysts can experience outsized swings as short-term traders lock in gains or reposition.
During the period, the company's fundamental story remained centered on its agenT-797 program, including the randomized Phase 2 trial in acute lung injury and critical illness initiated earlier in 2026, with preliminary data expected in the second half of the year. The absence of a fresh catalyst in the last 30 days likely allowed technical and liquidity factors to dominate price action.
What Drove INKT Stock Performance Over the Last Quarter
Over the most recent quarter, INKT moved broadly sideways, recovering from a late-July low before peaking in early October and retreating again. The multi-month narrative has been driven by MiNK's transition toward randomized clinical validation of agenT-797, capital-efficient expansion through non-dilutive collaborations such as the C-Further partnership for a PRAME-targeted pediatric oncology program, and disciplined cost management aimed at extending its cash runway.
Earlier in 2026, the stock traded materially higher, briefly reaching the mid-teens in March following clinical and partnership announcements. The subsequent drift reflects the market's wait-and-see posture ahead of randomized Phase 2 data, combined with the inherent financing risk that accompanies a pre-revenue, clinical-stage company.
INKT Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for INKT include preliminary data from the randomized Phase 2 trial of agenT-797 in acute lung injury and ARDS, which the company has guided for the second half of 2026. Progress on U.S. site activation and FDA feedback on trial design will also be closely watched. Additional watch items include updated financial results, cash runway and any financing activities, advancement of the C-Further pediatric oncology collaboration, and broader sector sentiment toward clinical-stage cell-therapy companies. I’m watching this closely as data readouts approach.
Exploring AI-Powered Trading Tools
In my analysis of names like INKT, I often turn to Tickeron’s suite of AI tools to cross-check patterns and compare performance across sectors. One resource I find particularly useful is the Trending AI Robots page, which curates top-performing automated strategies from a broad universe. These bots cover various holding periods and market conditions, offering a data-driven way to complement manual review of clinical-stage biotech names. For investors seeking systematic insights alongside traditional fundamentals, this section provides helpful perspective on how automated approaches are currently positioned.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INKT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for INKT moved above the 200-day moving average on September 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INKT's RSI Oscillator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 68 cases where INKT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +12.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where INKT advanced for three days, in 172 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
INKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 51 of 52 cases where INKT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INKT as a result. In 103 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for INKT turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 46 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
INKT moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INKT crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.867) is normal, around the industry mean (3.037). P/E Ratio (-4.485) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. INKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement